echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Stem Cells Dev: Research and analysis on the safety and effectiveness of allogeneic bone marrow mesenchymal stem cells exosomes in the treatment of severe COVID-19

    Stem Cells Dev: Research and analysis on the safety and effectiveness of allogeneic bone marrow mesenchymal stem cells exosomes in the treatment of severe COVID-19

    • Last Update: 2021-05-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The COVID-19 pandemic has brought huge economic and medical burdens to countries around the world.


    COVID-19 stem cells

    In April 2020, the study included 24 patients with severe COVID-19 and moderate to severe acute respiratory distress syndrome who were given ExoFlo treatment.


     

    The results showed that all safety endpoints were reached, and no adverse events occurred within 72 hours after the administration of ExoFlo.


     

    In general, after one treatment, the patient's clinical status and oxygen saturation were improved, and the average pressure of the arterial blood-oxygen ratio (PaO2/FiO2) increased by 192% (P <0.


    In short, because of its security, resilience oxygenation, reduced cytokine storm and rebuild the immune force, making ExoFlo become the treatment of severe COVID-19 potential therapies.


    immunity

     

    Original source:

     

    Vikram Sengupta, et al.


    ncbi.
    nlm.
    nih.
    gov/32380908/" target="_blank" rel="noopener">Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19 Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.